Applied DNA Sciences (NASDAQ:APDN) Releases Quarterly Earnings Results, Beats Expectations By $1.11 EPS

Applied DNA Sciences (NASDAQ:APDN) released its quarterly earnings results on Thursday. The technology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $1.11, Zacks reports. Applied DNA Sciences had a negative return on equity of 306.32% and a negative net margin of 222.33%. The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $0.95 million. During the same period in the prior year, the firm posted ($4.80) EPS.

Applied DNA Sciences Trading Up 2.9 %

Shares of APDN traded up $0.01 during trading hours on Friday, reaching $0.36. 424,759 shares of the company’s stock traded hands, compared to its average volume of 492,432. Applied DNA Sciences has a 12 month low of $0.33 and a 12 month high of $35.90. The stock has a market cap of $354,600.00, a PE ratio of -0.02 and a beta of 0.09. The firm’s 50 day simple moving average is $0.44 and its 200-day simple moving average is $5.39.

Analyst Ratings Changes

A number of equities research analysts have recently commented on APDN shares. StockNews.com began coverage on Applied DNA Sciences in a research note on Thursday. They set a “sell” rating on the stock. HC Wainwright dropped their price objective on Applied DNA Sciences from $7.00 to $1.50 and set a “buy” rating on the stock in a report on Monday, June 10th.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.